Health Condition 1: N181- Chronic kidney disease, stage 1 Health Condition 2: N182- Chronic kidney disease, stage 2 (mild) Health Condition 3: N183- Chronic kidney disease, stage 3 (moderate)
Conditions
Interventions
Intervention1: Placebo: Consisting of excipients only
Intervention2: Febuxostat 40mg: To be given orally once daily for 3 months
Control Intervention1: Febuxostat 20mg: To be given orally once daily f
Sponsors
Mohammad Shadab Ansari
Eligibility
Inclusion criteria
Inclusion criteria: Patients with Asymptomatic Hyperuricemia, with CKD stage 3 and below, attending Geneal Medicine/ Nephrology OPD and IPD Patients with Uric acid concentration 7 to 10 mg/dl Patients willing to give consent.
Exclusion criteria
Exclusion criteria: Patients with history of Gout. Patients with Alanine or Aspartate aminotransferase level more than 3-fold the upper limit defined at the institution. Patients on maintenance Hemodialysis therapy or Peritoneal dialysis. Patients with Kidney transplantation. Patients taking drugs like Thiazides or loop diuretics. Pregnant or lactating females Patients having received Uricosuric drugs in preceding 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Patients showing more than 10 percent decline in eGFR in all 3 groupsTimepoint: Baseline to end of the study period | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in eGFR in the 3 groupsTimepoint: Baseline to end of the study period;Changes in Uric acid levels of the 3 groupsTimepoint: Baseline to end of the study period;Development of CKD stage 5Timepoint: Baseline to end of the study period;Any Cardiovascular eventsTimepoint: Baseline to end of the study period | — |
Countries
India
Contacts
Public ContactMohammad Shadab Ansari
Jawaharlal Nehru Medical College
Outcome results
None listed